American Society of Clinical Oncology (ASCO) 2012 Annual Meeting video highlights, from OncLive TV.
Conferences > 2012 ASCO Annual Meeting
Dr. Michael Rotkowitz, from Cancer Treatment Centers of America, on the Dabrafenib Plus Trametinib Combination for Melanoma
Conferences > 2012 ASCO Annual Meeting
Roughly one-third of women with early-stage breast cancer develop intolerable adverse effects during aromatase inhibitor therapy.
Oncology & Biotech News > Clinical Trial Reports
Lately, business and government have done more to "move the needle" in changing healthcare delivery than physicians, scientists, and other clinical professionals.
Oncology & Biotech News > From the Editor
Combined neoadjuvant treatment with abiraterone acetate (Zytiga) plus standard hormonal therapy before prostatectomy eradicated or nearly eradicated tumors in 34% of patients with localized high-risk prostate cancer.
Conferences > 2012 ASCO Annual Meeting
Combining Two Targeted Therapies Stalls Disease Progression in Melanoma Patients With BRAF Mutations
A combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib has shown promising activity in patients with advanced melanoma.
Conferences > 2012 ASCO Annual Meeting
Olanzapine, an antipsychotic medication that has been used off-label to treat patients experiencing chemotherapy-induced nausea and vomiting (CINV).
Conferences > 2012 ASCO Annual Meeting
Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, on Neoadjuvant Hormonal Therapy Combined With Abiraterone Acetate
Conferences > 2012 ASCO Annual Meeting
Dr. Paul Chapman, from Memorial Sloan-Kettering Cancer Center, on Combining BRAF and MEK Inhibitors for Advanced Melanoma
Conferences > 2012 ASCO Annual Meeting
Dr. Maurie Markman, Cancer Treatment Centers of America, on Primary Care Physician Awareness of Long-Term Chemotherapy Side Effects
Conferences > 2012 ASCO Annual Meeting
Many primary care providers and some oncologists are unaware of the long-term effects of four chemotherapy drugs used to treat two of the most common forms of cancer.
Conferences > 2012 ASCO Annual Meeting
Dr. Shayma Kazmi, from Cancer Treatment Centers of America, on Olanzapine for Breakthrough Chemotherapy-Induced Nausea and Vomiting
Conferences > 2012 ASCO Annual Meeting
Dr. Andre Goy, from John Theurer Cancer Center, on Crizotinib for Pediatric Patients With ALCL
Conferences > 2012 ASCO Annual Meeting
Targeting the ALK gene with the oral agent crizotinib slowed or eliminated signs of tumor growth in pediatric patients with aggressive forms of neuroblastoma, ALCL, and IMTs.
Conferences > 2012 ASCO Annual Meeting
In men with primary squamous cell carcinoma of the penis who
have undergone surgery that removed all glanular epithelium a maximum 12-month follow-up
period is recommended.
Urologists in Cancer Care > Conference Highlights
When you consider how complex the system is, and how little training physicians get in medical school about coding, it stands to reason that practice leadership must emphasize its importance.
Urologists in Cancer Care > Practice Management
Now, with four new agents approved in the last two years and two promising agents in the pipeline, therapy selection and potential outcomes are changing.
Urologists in Cancer Care > Covery Story
Men with low-risk prostate cancer who have opted for active surveillance are about half as likely to experience pathologic progression or abandon active surveillance if they take a 5-ARI.
Urologists in Cancer Care > Conference Highlights
The Trials in Progress section supplies summaries of ongoing research in a broad range of cancer types.
Oncology & Biotech News > Trials in Progress
It is with great pleasure that I welcome you to the inaugural issue of Urologists in Cancer Care.
Urologists in Cancer Care > From the Editor
External Resources
American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747
Copyright HCPLive 2006-2012
Intellisphere, LLC. All Rights Reserved.
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747
Copyright HCPLive 2006-2012
Intellisphere, LLC. All Rights Reserved.